Vertex Pharmaceuticals Incorporated (VRTX) Q2 FY2026 Financial Statements: Revenue $3.33B, Net income $1.10B
More for Vertex Pharmaceuticals: Company index · 10-K and 10-Q summary · 8-K filings and events
PeriodQ2 FY2026
Published
Vertex Pharmaceuticals reported $3.33 billion in total revenue for Q2 FY2026, the quarter ended June 30, 2026, up 12.5% from a year earlier, and net income of $1.1 billion, or $4.31 per diluted share. The growth came from a shift inside the cystic fibrosis franchise rather than from Vertex's biggest medicine: ALYFTREK revenue reached $573.6 million, up 265.8%, while TRIKAFTA/KAFTRIO, still the largest product at $2.50 billion, was down 2.1% as patients transitioned to the newer once-daily therapy. Earnings grew more slowly than revenue, with net income up 6.5%, as commercial spending behind Vertex's non-cystic-fibrosis launches, a higher cost of sales on product mix and a higher effective tax rate all weighed on the bottom line. The results do not reflect Vertex's pending acquisition of Crinetics Pharmaceuticals, agreed in July and expected to close in the third quarter, which the raised full-year revenue guidance also excludes.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $3,333,900,000 | up 12.5% |
| Net income | $1,099,800,000 | up 6.5% |
| Diluted EPS | $4.31 | up 8.0% |
| TRIKAFTA/KAFTRIO revenue | $2,497,200,000 | down 2.1% |
| ALYFTREK revenue | $573,600,000 | up 265.8% |
About this file
| Ticker | VRTX |
|---|---|
| CIK | 0000875320 |
| Company | Vertex Pharmaceuticals Incorporated |
| Business type | pharmaceutical |
| Schema template | standard (product-revenue biopharmaceutical: revenue, cost of sales, R&D, acquired IPR&D, SG&A, operating income, net income, EPS; cash and marketable securities, total assets, equity; operating cash flow, capital expenditures, free cash flow) |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual dollars (not millions) |
VRTX annual income statement, balance sheet and cash flow
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Fiscal year | 2025 | 2024 | 2023 |
| Label | FY2025 | FY2024 | FY2023 |
| Period start | 2025-01-01 | 2024-01-01 | 2023-01-01 |
| Period end | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Period type | fiscal year | fiscal year | fiscal year |
| Source accession | 0000875320-26-000056 | 0000875320-26-000056 | 0000875320-26-000056 |
| Income statement | |||
| Product revenues net | 11,970,600,000 | 11,020,100,000 | 9,869,200,000 |
| Other revenues | 30,700,000 | 0 | 0 |
| Total revenues | 12,001,300,000 | 11,020,100,000 | 9,869,200,000 |
| Cost of sales | 1,651,300,000 | 1,530,500,000 | 1,262,200,000 |
| Research and development expenses | 3,909,500,000 | 3,630,300,000 | 3,162,900,000 |
| Acquired in process research and development expenses | 133,000,000 | 4,628,400,000 | 527,100,000 |
| Selling general and administrative expenses | 1,753,100,000 | 1,464,300,000 | 1,136,600,000 |
| Intangible asset impairment charge | 379,000,000 | 0 | 0 |
| Change in fair value of contingent consideration | 2,100,000 | -500,000 | -51,600,000 |
| Total costs and expenses | 7,828,000,000 | 11,253,000,000 | 6,037,200,000 |
| Operating income | 4,173,300,000 | -232,900,000 | 3,832,000,000 |
| Interest income | 490,900,000 | 598,100,000 | 614,700,000 |
| Interest expense | -13,300,000 | -30,600,000 | -44,100,000 |
| Other income expense net | -7,700,000 | -86,100,000 | -22,800,000 |
| Income before income taxes | 4,643,200,000 | 248,500,000 | 4,379,800,000 |
| Provision for income taxes | 690,000,000 | 784,100,000 | 760,200,000 |
| Basic shares | 255,700,000 | 257,900,000 | 257,700,000 |
| Diluted shares | 258,000,000 | 257,900,000 | 260,500,000 |
| Net income | 3,953,200,000 | -535,600,000 | 3,619,600,000 |
| Basic EPS | 15.46 | -2.08 | 14.05 |
| Diluted EPS | 15.32 | -2.08 | 13.89 |
| Gross profit | 10,350,000,000 | 9,489,600,000 | 8,607,000,000 |
| Interest income net | 477,600,000 | 567,500,000 | 570,600,000 |
| Cash flow | |||
| Stock based compensation expense | 685,900,000 | 698,500,000 | 581,200,000 |
| Depreciation and amortization expense | 209,800,000 | 207,200,000 | 181,300,000 |
| Operating cash flow | 3,631,400,000 | -492,600,000 | 3,537,300,000 |
| Capital expenditures | -437,600,000 | -297,700,000 | -200,400,000 |
| Investing cash flow | -945,400,000 | -3,770,000,000 | -3,141,700,000 |
| Repurchases of common stock | -2,017,400,000 | -1,177,100,000 | -427,600,000 |
| Financing cash flow | -2,261,300,000 | -1,494,900,000 | -562,200,000 |
| Cash paid for income taxes | 1,566,700,000 | 1,082,100,000 | 1,677,300,000 |
| Free cash flow | 3,193,800,000 | -790,300,000 | 3,336,900,000 |
| Balance sheet | |||
| Cash and cash equivalents | 5,084,800,000 | 4,569,600,000 | |
| Marketable securities | 1,523,300,000 | 1,546,300,000 | |
| Accounts receivable net | 2,052,800,000 | 1,609,400,000 | |
| Inventories | 1,686,800,000 | 1,205,400,000 | |
| Prepaid expenses and other current assets | 853,300,000 | 665,700,000 | |
| Total current assets | 11,201,000,000 | 9,596,400,000 | |
| Property and equipment net | 1,520,300,000 | 1,227,800,000 | |
| Goodwill | 1,088,000,000 | 1,088,000,000 | |
| Other intangible assets net | 424,200,000 | 825,900,000 | |
| Deferred tax assets | 2,897,900,000 | 2,331,100,000 | |
| Operating lease assets | 1,562,700,000 | 1,356,800,000 | |
| Long term marketable securities | 5,712,300,000 | 5,107,900,000 | |
| Other assets | 1,236,600,000 | 999,300,000 | |
| Total assets | 25,643,000,000 | 22,533,200,000 | |
| Accounts payable | 461,700,000 | 413,000,000 | |
| Accrued expenses | 2,971,200,000 | 2,788,600,000 | |
| Other current liabilities | 428,300,000 | 363,000,000 | |
| Total current liabilities | 3,861,200,000 | 3,564,600,000 | |
| Long term operating lease liabilities | 1,846,500,000 | 1,544,400,000 | |
| Other long term liabilities | 1,269,500,000 | 1,014,600,000 | |
| Total liabilities | 6,977,200,000 | 6,123,600,000 | |
| Additional paid in capital | 5,119,200,000 | 6,672,400,000 | |
| Retained earnings | 13,560,000,000 | 9,606,800,000 | |
| Total shareholders equity | 18,665,800,000 | 16,409,600,000 | |
| Cash and marketable securities | 12,320,400,000 | 11,223,800,000 | |
| Common shares issued and outstanding | 253,991,224 | 256,940,382 | |
| Total debt | 0 | 0 | |
| Revenue by product | |||
| Trikafta kaftrio | 10,312,700,000 | 10,238,600,000 | 8,944,700,000 |
| Alyftrek | 837,800,000 | 0 | 0 |
| Other product revenues | 820,100,000 | 781,500,000 | 924,500,000 |
| Total product revenues net | 11,970,600,000 | 11,020,100,000 | 9,869,200,000 |
| Revenue by geography | |||
| United states | 7,548,600,000 | 6,684,900,000 | 6,040,400,000 |
| Europe | 3,460,300,000 | 3,453,900,000 | 3,109,000,000 |
| Other international | 992,400,000 | 881,300,000 | 719,800,000 |
| Total outside the united states | 4,452,700,000 | 4,335,200,000 | 3,828,800,000 |
| Total revenues | 12,001,300,000 | 11,020,100,000 | 9,869,200,000 |
VRTX quarterly income statement, balance sheet and cash flow
| Q2 2026 | Q2 2025 | |
|---|---|---|
| Fiscal year | 2026 | 2025 |
| Fiscal quarter | 2 | 2 |
| Label | Q2 2026 | Q2 2025 |
| Period start | 2026-04-01 | 2025-04-01 |
| Period end | 2026-06-30 | 2025-06-30 |
| Period type | three months | three months |
| Source accession | 0000875320-26-000259 | 0000875320-26-000259 |
| Income statement | ||
| Product revenues net | 3,333,900,000 | 2,944,000,000 |
| Other revenues | 0 | 20,700,000 |
| Total revenues | 3,333,900,000 | 2,964,700,000 |
| Cost of sales | 489,200,000 | 407,500,000 |
| Research and development expenses | 993,800,000 | 978,400,000 |
| Acquired in process research and development expenses | 21,400,000 | 2,200,000 |
| Selling general and administrative expenses | 582,200,000 | 424,600,000 |
| Intangible asset impairment charge | 0 | 0 |
| Change in fair value of contingent consideration | 400,000 | 900,000 |
| Total costs and expenses | 2,087,000,000 | 1,813,600,000 |
| Operating income | 1,246,900,000 | 1,151,100,000 |
| Interest income net | 120,600,000 | 118,700,000 |
| Other income expense net | 24,300,000 | 13,200,000 |
| Income before income taxes | 1,391,800,000 | 1,283,000,000 |
| Provision for income taxes | 292,000,000 | 250,100,000 |
| Net income | 1,099,800,000 | 1,032,900,000 |
| Basic shares | 253,700,000 | 256,700,000 |
| Diluted shares | 255,200,000 | 258,900,000 |
| Basic EPS | 4.34 | 4.02 |
| Diluted EPS | 4.31 | 3.99 |
| Gross profit | 2,844,700,000 | 2,557,200,000 |
| Balance sheet | ||
| Cash and cash equivalents | 6,143,500,000 | |
| Marketable securities | 1,708,900,000 | |
| Accounts receivable net | 2,134,300,000 | |
| Inventories | 1,765,100,000 | |
| Prepaid expenses and other current assets | 791,900,000 | |
| Total current assets | 12,543,700,000 | |
| Property and equipment net | 1,665,000,000 | |
| Goodwill | 1,088,000,000 | |
| Other intangible assets net | 412,800,000 | |
| Deferred tax assets | 3,010,900,000 | |
| Operating lease assets | 1,662,900,000 | |
| Long term marketable securities | 5,789,100,000 | |
| Other assets | 1,250,900,000 | |
| Total assets | 27,423,300,000 | |
| Accounts payable | 429,500,000 | |
| Accrued expenses | 3,179,000,000 | |
| Other current liabilities | 329,400,000 | |
| Total current liabilities | 3,937,900,000 | |
| Long term operating lease liabilities | 1,977,600,000 | |
| Other long term liabilities | 1,259,900,000 | |
| Total liabilities | 7,175,400,000 | |
| Additional paid in capital | 4,505,700,000 | |
| Retained earnings | 15,691,200,000 | |
| Total shareholders equity | 20,247,900,000 | |
| Cash and marketable securities | 13,641,500,000 | |
| Common shares issued and outstanding | 253,347,555 | |
| Total debt | 0 | |
| Revenue by product | ||
| Trikafta kaftrio | 2,497,200,000 | 2,551,100,000 |
| Alyftrek | 573,600,000 | 156,800,000 |
| Other cf product revenues | 137,100,000 | 193,700,000 |
| Total cf product revenues net | 3,207,900,000 | 2,901,600,000 |
| Casgevy | 76,400,000 | 30,400,000 |
| Journavx | 49,600,000 | 12,000,000 |
| Total product revenues net | 3,333,900,000 | 2,944,000,000 |
| Revenue by geography | ||
| United states | 2,056,400,000 | 1,848,200,000 |
| Europe | 977,700,000 | 910,900,000 |
| Other international | 299,800,000 | 205,600,000 |
| Total outside the united states | 1,277,500,000 | 1,116,500,000 |
| Total revenues | 3,333,900,000 | 2,964,700,000 |
VRTX year-to-date income statement and cash flow
| Six months ended June 30, 2026 | |
|---|---|
| Label | Six months ended June 30, 2026 |
| Period start | 2026-01-01 |
| Period end | 2026-06-30 |
| Period type | six months |
| Source accession | 0000875320-26-000259 |
| Income statement | |
| Product revenues net | 6,320,800,000.0 |
| Other revenues | 0.0 |
| Total revenues | 6,320,800,000.0 |
| Cost of sales | 882,000,000.0 |
| Research and development expenses | 1,955,400,000.0 |
| Acquired in process research and development expenses | 21,900,000.0 |
| Selling general and administrative expenses | 1,075,900,000.0 |
| Intangible asset impairment charge | 0.0 |
| Change in fair value of contingent consideration | 600,000.0 |
| Total costs and expenses | 3,935,800,000.0 |
| Operating income | 2,385,000,000.0 |
| Interest income net | 235,400,000.0 |
| Other income expense net | 24,300,000.0 |
| Income before income taxes | 2,644,700,000.0 |
| Provision for income taxes | 513,500,000.0 |
| Net income | 2,131,200,000.0 |
| Basic shares | 253,900,000.0 |
| Diluted shares | 255,700,000.0 |
| Basic EPS | 8.39 |
| Diluted EPS | 8.33 |
| Gross profit | 5,438,800,000.0 |
| Cash flow | |
| Stock based compensation expense | 336,600,000.0 |
| Depreciation and amortization expense | 112,400,000.0 |
| Operating cash flow | 2,553,500,000.0 |
| Capital expenditures | -245,600,000.0 |
| Investing cash flow | -477,700,000.0 |
| Repurchases of common stock | -806,400,000.0 |
| Financing cash flow | -965,500,000.0 |
| Cash paid for income taxes | 501,500,000.0 |
| Free cash flow | 2,307,900,000.0 |
| Revenue by product | |
| Trikafta kaftrio | 4,851,900,000.0 |
| Alyftrek | 998,000,000.0 |
| Other cf product revenues | 273,000,000.0 |
| Total cf product revenues net | 6,122,900,000.0 |
| Casgevy | 119,300,000.0 |
| Journavx | 78,600,000.0 |
| Total product revenues net | 6,320,800,000.0 |
| Revenue by geography | |
| United states | 3,832,300,000.0 |
| Europe | 1,927,700,000.0 |
| Other international | 560,800,000.0 |
| Total outside the united states | 2,488,500,000.0 |
| Total revenues | 6,320,800,000.0 |
VRTX trailing twelve month income statement and cash flow
| Trailing twelve months ended June 30, 2026 | |
|---|---|
| Label | Trailing twelve months ended June 30, 2026 |
| Period start | 2025-07-01 |
| Period end | 2026-06-30 |
| Period type | trailing twelve months |
| Source accession | 0000875320-26-000056; 0000875320-26-000259 |
| Derivation | fiscal year 2025 plus the six months ended June 30, 2026 less the six months ended June 30, 2025 |
| Income statement | |
| Product revenues net | 12,587,200,000.0 |
| Other revenues | 0.0 |
| Total revenues | 12,587,200,000.0 |
| Cost of sales | 1,762,800,000.0 |
| Research and development expenses | 3,906,800,000.0 |
| Acquired in process research and development expenses | 132,900,000.0 |
| Selling general and administrative expenses | 2,008,000,000.0 |
| Intangible asset impairment charge | 0.0 |
| Change in fair value of contingent consideration | -400,000.0 |
| Total costs and expenses | 7,810,100,000.0 |
| Operating income | 4,777,100,000.0 |
| Interest income net | 476,400,000.0 |
| Other income expense net | 21,000,000.0 |
| Income before income taxes | 5,274,500,000.0 |
| Provision for income taxes | 869,300,000.0 |
| Net income | 4,405,200,000.0 |
| Gross profit | 10,824,400,000.0 |
| Cash flow | |
| Stock based compensation expense | 689,100,000.0 |
| Depreciation and amortization expense | 222,100,000.0 |
| Operating cash flow | 4,292,900,000.0 |
| Capital expenditures | -496,800,000.0 |
| Investing cash flow | -882,800,000.0 |
| Repurchases of common stock | -2,005,900,000.0 |
| Financing cash flow | -2,197,200,000.0 |
| Cash paid for income taxes | 1,370,500,000.0 |
| Free cash flow | 3,796,100,000.0 |
| Revenue by geography | |
| United states | 7,869,200,000.0 |
| Europe | 3,650,500,000.0 |
| Other international | 1,067,500,000.0 |
| Total outside the united states | 4,718,000,000.0 |
| Total revenues | 12,587,200,000.0 |
Adjustments
| Value | |
|---|---|
| Splits applied | none |
| ADR ratio | n/a |
| FX | none applied; the company reports in U.S. dollars |
Notes
- Every figure here is stated in actual U.S. dollars. Both filings print their statements in millions (share counts on the balance sheet are printed in full), and the scale stated at the head of each table has been applied; the note read for each statement is listed under "units_notes_seen".
- Vertex is a single-segment commercial-stage biopharmaceutical company, so the record uses a standard product-revenue template: total revenues, cost of sales, research and development, acquired in-process research and development, selling, general and administrative expenses, operating income, net income and per-share amounts; cash and marketable securities, total assets and shareholders' equity; operating cash flow, capital expenditures and free cash flow. Revenue is additionally split by product and by geography, which is how the company itself describes the business in its segment note.
- Sources. The three fiscal years come from the consolidated statements in the FY2025 Form 10-K (accession 0000875320-26-000056), filed February 13, 2026. The second quarter of 2026, the second quarter of 2025 and the six-month columns come from the condensed consolidated statements in the Form 10-Q for the quarter ended June 30, 2026 (accession 0000875320-26-000259), filed August 4, 2026.
- Periods the two filings present, and therefore everything this record holds: fiscal years 2025, 2024 and 2023 on the income statement and the cash flow statement; December 31, 2025 and December 31, 2024 on the balance sheet; the three months ended June 30, 2026 and June 30, 2025; the six months ended June 30, 2026 and June 30, 2025; and the balance sheet at June 30, 2026. Fiscal 2023 therefore carries no balance sheet, because the 10-K's balance sheet presents only two year-ends.
- The quarterly entries carry no cash flow block. The 10-Q presents its cash flow statement for the six months ended June 30, 2026 and 2025 only, and the company's second-quarter earnings release contains no cash flow statement, so no discrete three-month operating cash flow or free cash flow figure was published for either quarter. Six-month cash flows are in "year_to_date" and "prior_year_to_date".
- The second quarter of 2025 carries no balance sheet: the 10-Q's balance sheet columns are June 30, 2026 and December 31, 2025, and a June 30, 2025 balance sheet is not presented in either filing.
- Cash flow line items are stated as the filings print them, so cash outflows carry a negative sign. "capital_expenditures" is the "Purchases of property and equipment" line. "free_cash_flow" is operating cash flow less capital expenditures and is not a figure the company itself reports.
- "gross_profit" is total revenues less cost of sales. Vertex does not print a gross profit subtotal on the face of its income statement, and cost of sales is struck against total revenues.
- "interest_income_net" for the fiscal years is interest income less interest expense as the 10-K prints those two lines separately ($490.9 million less $13.3 million in 2025, $598.1 million less $30.6 million in 2024, and $614.7 million less $44.1 million in 2023). The 10-Q prints a single "Interest income, net" line, which is used directly for the quarters and six-month periods.
- "total_debt" is zero in every period: neither balance sheet carries any borrowings. In July 2026, after the June 30, 2026 balance-sheet date, Vertex terminated the $500.0 million revolving credit agreement it had entered into in 2022 and entered into a new $500.0 million senior unsecured revolving facility that matures on July 30, 2031. On July 30, 2026 it also entered into a term loan credit agreement providing for a $4.5 billion senior unsecured delayed-draw term loan A facility, amounts under which would be used to finance a portion of the pending acquisition of Crinetics Pharmaceuticals, Inc. The Q2 2026 10-Q (accession 0000875320-26-000259) states that Vertex had not drawn upon either the new revolving facility or the term loan facility as of that filing, so "total_debt" remains zero.
- "cash_and_marketable_securities" is the sum of cash and cash equivalents, short-term marketable securities and long-term marketable securities: $13,641.5 million at June 30, 2026, $12,320.4 million at December 31, 2025 and $11,223.8 million at December 31, 2024.
- The trailing-twelve-month block is derived, not filed: fiscal year 2025 plus the six months ended June 30, 2026 less the six months ended June 30, 2025. It carries no weighted-average share count or per-share amount, because a weighted average over that window is not a figure either filing publishes and summing four quarters of per-share data would not produce one.
- The fiscal 2024 net loss of $535.6 million follows from $4,628.4 million of acquired in-process research and development expense recorded that year, against $133.0 million in 2025 and $527.1 million in 2023. Operating cash flow was also negative in 2024, at an outflow of $492.6 million.
- The product split is reported at different levels of detail in the two filings, so the captions differ by period. The 10-K's annual table shows TRIKAFTA/KAFTRIO, ALYFTREK and a single "Other product revenues" line; the 10-Q's quarterly and six-month table separates other cystic fibrosis products from CASGEVY and JOURNAVX. The geographic split uses the same captions in both. Because the two product tables are not on the same basis, the trailing-twelve-month block carries the geographic split only.
- No stock split, foreign-currency translation or depositary-share adjustment applies. The company has had no stock split in the period covered, reports in U.S. dollars, and its shares are listed directly rather than as depositary receipts.
Uncertainties
- There is no discrete three-month cash flow figure for the second quarter of 2026 or the second quarter of 2025 anywhere in these filings, so none is reported. Anyone needing a quarterly operating cash flow would have to difference the six-month column against a first-quarter figure, which these two filings do not contain.
- The trailing-twelve-month figures are arithmetic from three published columns rather than a period any filing reports. They are exact on that construction, but they are not an audited or filed period.
- Fiscal 2023 has no balance sheet in this record, and the second quarter of 2025 has neither a balance sheet nor a cash flow statement. These are gaps in what the two filings present, not omissions in the reading.
- Free cash flow is a derived measure, not one Vertex reports. It is stated here as operating cash flow less purchases of property and equipment, with no other deduction.
Prior year to date
| Six months ended June 30, 2025 | |
|---|---|
| Label | Six months ended June 30, 2025 |
| Period start | 2025-01-01 |
| Period end | 2025-06-30 |
| Period type | six months |
| Source accession | 0000875320-26-000259 |
| Income statement | |
| Product revenues net | 5,704,200,000.0 |
| Other revenues | 30,700,000.0 |
| Total revenues | 5,734,900,000.0 |
| Cost of sales | 770,500,000.0 |
| Research and development expenses | 1,958,100,000.0 |
| Acquired in process research and development expenses | 22,000,000.0 |
| Selling general and administrative expenses | 821,000,000.0 |
| Intangible asset impairment charge | 379,000,000.0 |
| Change in fair value of contingent consideration | 3,100,000.0 |
| Total costs and expenses | 3,953,700,000.0 |
| Operating income | 1,781,200,000.0 |
| Interest income net | 236,600,000.0 |
| Other income expense net | -4,400,000.0 |
| Income before income taxes | 2,013,400,000.0 |
| Provision for income taxes | 334,200,000.0 |
| Net income | 1,679,200,000.0 |
| Basic shares | 256,800,000.0 |
| Diluted shares | 259,200,000.0 |
| Basic EPS | 6.54 |
| Diluted EPS | 6.48 |
| Gross profit | 4,964,400,000.0 |
| Cash flow | |
| Stock based compensation expense | 333,400,000.0 |
| Depreciation and amortization expense | 100,100,000.0 |
| Operating cash flow | 1,892,000,000.0 |
| Capital expenditures | -186,400,000.0 |
| Investing cash flow | -540,300,000.0 |
| Repurchases of common stock | -817,900,000.0 |
| Financing cash flow | -1,029,600,000.0 |
| Cash paid for income taxes | 697,700,000.0 |
| Free cash flow | 1,705,600,000.0 |
| Revenue by product | |
| Trikafta kaftrio | 5,086,600,000.0 |
| Alyftrek | 210,700,000.0 |
| Other cf product revenues | 349,000,000.0 |
| Total cf product revenues net | 5,646,300,000.0 |
| Casgevy | 44,600,000.0 |
| Journavx | 13,300,000.0 |
| Total product revenues net | 5,704,200,000.0 |
| Revenue by geography | |
| United states | 3,511,700,000.0 |
| Europe | 1,737,500,000.0 |
| Other international | 485,700,000.0 |
| Total outside the united states | 2,223,200,000.0 |
| Total revenues | 5,734,900,000.0 |
Company details
| Value | |
|---|---|
| Name | Vertex Pharmaceuticals Inc / Ma |
| Ticker | VRTX |
| CIK | 0000875320 |
| Exchange | Nasdaq |
| State | Massachusetts |
| Incorporation | Massachusetts |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
Fiscal period
| FY2026 | |
|---|---|
| Fiscal year | 2026 |
| Fiscal period | Q2 |
| Tag | FY26Q2 |
| Period end | 2026-06-30 |
| Form | 10-Q |
| Accession | 0000875320-26-000259 |
| Fiscal year end | 1231 |
| Source | facts |
Source filings
| Role | Current | Form | Fiscal year | Fiscal period | Tag | Period end | Filed | Accession | Url | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| annual | no | 10-K | 2025 | FY | FY25 | 2025-12-31 | 2026-02-13 | 0000875320-26-000056 | https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm | reported |
| quarterly | yes | 10-Q | 2026 | Q2 | FY26Q2 | 2026-06-30 | 2026-08-04 | 0000875320-26-000259 | https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/0000875320-26-000259-index.htm | facts |
FAQ · Vertex Pharmaceuticals financial statements
How much revenue did Vertex Pharmaceuticals report in Q2 FY2026?
Vertex Pharmaceuticals reported $3.33 billion in total revenue for Q2 FY2026, the quarter ended June 30, 2026. That is up 12.5% from $2.96 billion in the same quarter a year earlier.
How much did Vertex Pharmaceuticals earn per share in Q2 FY2026?
Vertex Pharmaceuticals earned $4.31 per diluted share in Q2 FY2026, up 8.0% from $3.99 a year earlier, on net income of $1.1 billion.
Is TRIKAFTA revenue still growing for Vertex Pharmaceuticals?
No. TRIKAFTA/KAFTRIO, the largest medicine Vertex Pharmaceuticals sells, generated $2.50 billion in Q2 FY2026, down 2.1% from $2.55 billion a year earlier, as cystic fibrosis patients moved to the newer once-daily ALYFTREK.
How fast is ALYFTREK growing for Vertex Pharmaceuticals?
ALYFTREK, the once-daily cystic fibrosis triple combination Vertex Pharmaceuticals introduced after TRIKAFTA, generated $573.6 million in Q2 FY2026, up 265.8% from $156.8 million a year earlier, making it the main source of the company's revenue growth.
Where can I get Vertex Pharmaceuticals Incorporated (VRTX) financial data in machine-readable form?
Ticker Scout publishes Vertex Pharmaceuticals Incorporated's financial statements as JSON at https://tickerscout.ai/vrtx/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/vrtx/narrative.md and https://tickerscout.ai/vrtx/events.md. Vertex Pharmaceuticals Incorporated's SEC CIK is 0000875320. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Vertex Pharmaceuticals Incorporated (VRTX) next file with the SEC?
Vertex Pharmaceuticals Incorporated (VRTX) is expected to file its next Form 10-Q with the SEC on or around November 3, 2026. That date is a projection rather than a company-announced date: it is derived from Vertex Pharmaceuticals Incorporated's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-30, SEC accession 0000875320-26-000259.
Related companies
How this page was built
This page was built from two of Vertex Pharmaceuticals Incorporated's own filings with the SEC, read one at a time. Nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names four such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from Vertex Pharmaceuticals Incorporated's SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.